Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Current Deferred Revenue for 11 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 64.72% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, down 64.72% year-over-year, with the annual reading at $7.3 million for FY2025, 64.72% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $7.3 million at Intellia Therapeutics, down from $12.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $127.2 million in Q4 2021, with the low at $7.3 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $57.9 million, with a median of $52.9 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue surged 166.47% in 2021, then plummeted 72.64% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $127.2 million in 2021, then plummeted by 49.88% to $63.8 million in 2022, then fell by 4.36% to $61.0 million in 2023, then tumbled by 66.13% to $20.7 million in 2024, then plummeted by 64.72% to $7.3 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $7.3 million, $12.2 million, and $29.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.